PPD10558
Phase 2Small molecule
PPD10558 is one of 19 small molecule programs targeting Myalgia. It is currently in Phase 2.
1
Indications
1
Total Trials
0
Active Trials
18
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
22 competitors in Myalgia
#DrugCompanyPhaseTrials
1Aleve
Alnylam PharmaceuticalsApproved
Bayer Aspirin
BayerApproved
Olumiant
Eli LillyApproved
Voltaren
NovartisApproved
Advil
KKenvue Brands
Approved
Xylocaine
MMEDRx USA, Inc.
Approved
Indocin
LLife Extension Foundation Inc.
Approved
Aspercreme Warming
AAveritas Pharma, Inc.
Approved
Oruvail
WWyeth-Lederle Vaccines
Approved
Esmeron
FFresenius Kabi Oncology Ltd.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Myalgia1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PPD10558. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- FFuriex Pharmaceuticals, Inc